Ciclazindol

Ciclazindol (WY-23409) is an antidepressant and anorectic^[2] drug of the tetracyclic^{[citation needed]} chemical class that was developed in the mid to late 1970s, but was never marketed.^[3][4] It acts as a norepinephrine reuptake inhibitor, and to a lesser extent as a dopamine reuptake inhibitor.^[3][5] Ciclazindol has no effects on the SERT, 5-HT receptors, mACh receptors, or α-adrenergic receptors, and has only weak affinity for the H₁ receptor.^[5][6][7] As suggested by its local anesthetic properties,^[6] ciclazindol may also inhibit sodium channels. It is known to block potassium channels as well.^[8][9]

Ciclazindol

Clinical data
Routes of administration	Oral
ATC code	none
Pharmacokinetic data
Metabolism	Renal[1]
Elimination half-life	~32 hours[1]
Excretion	Urine, feces[1]
Identifiers
IUPAC name 10-(3-Chlorophenyl)-3,4-dihydro-2H-pyrimido[1,2-a]indol-10-ol
CAS Number	37751-39-6
PubChem CID	37825
ChemSpider	34683
UNII	Y3I9520J7P
KEGG	D03486
ChEMBL	ChEMBL1192491
CompTox Dashboard (EPA)	DTXSID50865883
Chemical and physical data
Formula	C17H15ClN2O
Molar mass	298.77 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1cccc(c1)C3(O)c4c(N2\C3=N/CCC2)cccc4

The dosage in human volunteers is stated to be 25 mg daily.^[1] However, doses of up to 200 mg have also been reported.^[2] This is surprising since the dosage of mazindol is only 2-4 mg per day.

Ciclazindol is reported to have an IC₅₀ of 1.3 nM for the dopamine transporter (cmp 23).^[10]

See also

• Mazindol
• Setazindol